SynthesisEmerging microbes & infections2025
Monkeypox in South Asia: a systematic review.
Synthesis in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Serologic evidence of mpox virus exposure among people living with human immunodeficiency virus in Thailand predating clinical recognition during the 2022 outbreak.IJID regions · 2026Article
- Mpox in South Asia: A Narrative Review on Epidemiology, Preparedness, and Preventive Strategies.Health science reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Monkeypox (Mpox) has emerged as a significant public health concern globally and in South Asia. Therefore, this systematic review aimed to provide a synthesis of the epidemiological pattern, clinical features, disease severity, and mitigation strategies in the region. A systematic review was conducted across four databases including PubMed, Scopus, Web of Science, and Ovid from inception to August 2024. Out of 2,430 studies, only 19 met the inclusion criteria with 111 confirmed Mpox cases. Forty percent (44) of patients were males and 45.9% (51) did not specify their sex. Young to middle-aged adults were most affected, with rare cases in a neonate. Around two-thirds (73.0%, 81) of Mpox patients were from India, followed by Pakistan (16.2%, 18) and Nigeria (resident in India) (9.9%, 11). Sixty-eight percent (76) of Mpox patients reported recent travel, particularly to UAE (27%, 21) and Saudi Arabia (26.3%, 20). Common signs and symptoms among cases were skin lesion (92.8%, 103), fever (82.0%, 91), lymphadenopathy (65.8%, 73), muscle ache (27.0%, 30), and genital and perianal lesions (17.1%, 19). Co-infection with herpes simplex virus and varicella zoster virus led to difficulty in diagnosis. Nearly all the studies used polymerase chain reaction for diagnosis. Public health responses varied across countries, including enhanced surveillance, contact tracing, and awareness campaigns, but vaccine availability remained limited. Mpox in South Asia was largely linked to travel-related transmission and primarily affected younger adults. Strengthening surveillance systems, a syndemic approach, diagnostic capacity, and targeted interventions are crucial to controlling its spread.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.